NASDAQ:EPZM Epizyme Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Epizyme Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.81 -0.45 (-3.39 %) (As of 09/21/2020 12:00 AM ET) Add Compare Share Today's Range$12.03Now: $12.81▼$13.0450-Day Range$12.00MA: $12.72▼$14.3752-Week Range$9.73Now: $12.81▼$27.82Volume1.51 million shsAverage Volume1.07 million shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/ABeta1.92 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingEpizyme has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.00, Epizyme has a forecasted upside of 126.4% from its current price of $12.81.Amount of Analyst CoverageEpizyme has only been the subject of 1 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesEpizyme has received 467 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEpizyme has received 366 “underperform” votes. (Add your “underperform” vote.)Community SentimentEpizyme has received 56.06% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote “Outperform” if you believe EPZM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEpizyme does not currently pay a dividend.Dividend GrowthEpizyme does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Epizyme insiders have bought 703.34% more of their company's stock than they have sold. Specifically, they have bought $994,165.00 in company stock and sold $123,754.00 in company stock.Percentage Held by InsidersOnly 16.30% of the stock of Epizyme is held by insiders.Percentage Held by Institutions90.93% of the stock of Epizyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Epizyme are expected to grow in the coming year, from ($2.33) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Epizyme is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Epizyme is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEpizyme has a P/B Ratio of 3.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.16 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EPZM Previous Symbol CUSIPN/A CIK1571498 Webwww.epizyme.com Phone617-229-5872Debt Debt-to-Equity Ratio0.27 Current Ratio11.57 Quick Ratio11.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$23.80 million Price / Sales54.62 Cash FlowN/A Price / Cash FlowN/A Book Value$3.22 per share Price / Book3.98Profitability EPS (Most Recent Fiscal Year)($1.93) Net Income$-170,290,000.00 Net Margins-1,459.72% Return on Equity-72.65% Return on Assets-49.31%Miscellaneous Employees124 Outstanding Shares101,478,000Market Cap$1.30 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $12.81 -0.45 (-3.39 %) (As of 09/21/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive EPZM News and Ratings via Email Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter. Epizyme (NASDAQ:EPZM) Frequently Asked Questions How has Epizyme's stock price been impacted by COVID-19? Epizyme's stock was trading at $18.46 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EPZM stock has decreased by 30.6% and is now trading at $12.81. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Epizyme? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Epizyme. When is Epizyme's next earnings date? Epizyme is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Epizyme. How were Epizyme's earnings last quarter? Epizyme Inc (NASDAQ:EPZM) announced its quarterly earnings results on Tuesday, August, 4th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.02. The biopharmaceutical company had revenue of $2.47 million for the quarter, compared to analyst estimates of $4.67 million. Epizyme had a negative return on equity of 72.65% and a negative net margin of 1,459.72%. View Epizyme's earnings history. What price target have analysts set for EPZM? 8 analysts have issued 1-year price objectives for Epizyme's shares. Their forecasts range from $16.00 to $36.00. On average, they anticipate Epizyme's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 126.4% from the stock's current price. View analysts' price targets for Epizyme. Who are some of Epizyme's key competitors? Some companies that are related to Epizyme include Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), HUTCHISON CHINA/S (HCM), United Therapeutics (UTHR), MorphoSys (MOR), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Arena Pharmaceuticals (ARNA), Evotec (EVTCY), FibroGen (FGEN), Allakos (ALLK), ChemoCentryx (CCXI), Biohaven Pharmaceutical (BHVN) and Legend Biotech (LEGN). View all competitors. What other stocks do shareholders of Epizyme own? Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Novavax (NVAX), Micron Technology (MU), Pfizer (PFE), Crispr Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Heron Therapeutics (HRTX), Ionis Pharmaceuticals (IONS) and TG Therapeutics (TGTX). Who are Epizyme's key executives? Epizyme's management team includes the following people: Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory BoardDr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory BoardMr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38) What is Epizyme's stock symbol? Epizyme trades on the NASDAQ under the ticker symbol "EPZM." Who are Epizyme's major shareholders? Epizyme's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.11%), Victory Capital Management Inc. (2.26%), FMR LLC (1.98%), Charles Schwab Investment Management Inc. (0.53%), Nuveen Asset Management LLC (0.45%) and Bank of New York Mellon Corp (0.35%). Company insiders that own Epizyme stock include David M Mott, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore and Shefali Agarwal. View institutional ownership trends for Epizyme. Which major investors are selling Epizyme stock? EPZM stock was sold by a variety of institutional investors in the last quarter, including Atom Investors LP, Federated Hermes Inc., Rhenman & Partners Asset Management AB, First Trust Advisors LP, AlphaCrest Capital Management LLC, Alps Advisors Inc., Bank of America Corp DE, and Principal Financial Group Inc.. Company insiders that have sold Epizyme company stock in the last year include Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore, and Shefali Agarwal. View insider buying and selling activity for Epizyme. Which major investors are buying Epizyme stock? EPZM stock was bought by a variety of institutional investors in the last quarter, including Man Group plc, Greenspring Associates LLC, Vanguard Group Inc., Teacher Retirement System of Texas, Pier Capital LLC, Victory Capital Management Inc., Point72 Asset Management L.P., and California State Teachers Retirement System. View insider buying and selling activity for Epizyme. How do I buy shares of Epizyme? Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Epizyme's stock price today? One share of EPZM stock can currently be purchased for approximately $12.81. How big of a company is Epizyme? Epizyme has a market capitalization of $1.30 billion and generates $23.80 million in revenue each year. The biopharmaceutical company earns $-170,290,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Epizyme employs 124 workers across the globe. What is Epizyme's official website? The official website for Epizyme is www.epizyme.com. How can I contact Epizyme? Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
